All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Galan, 2021 0.94 [0.51; 1.73]
GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
HAHPS, 2020 7.00 [0.80; 60.90]
Hung et al., 2020 0.47 [0.01; 24.30]
Nojomi, 2020 0.49 [0.04; 5.58]
Nojomi, 2020 2.04 [0.18; 23.27]
Ren, 2020 (REV) 1.00 [0.02; 55.80]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
1.01 [0.71 ; 1.43 ] Galan, 2021, GS-US-540-5773 (Goldman), 2020, HAHPS, 2020, Hung et al., 2020, Nojomi, 2020, Nojomi, 2020, Ren, 2020 (REV), Solaymani-Dodaran, 2021 8 0% 1,370 moderate not evaluable deaths (time to event analysis only)detailed results Galan, 2021 0.94 [0.51; 1.73]
0.94 [0.51 ; 1.73 ] Galan, 2021 1 0% 168 NA not evaluable clinical deteriorationdetailed results HAHPS, 2020 1.07 [0.63; 1.82]
1.07 [0.63 ; 1.82 ] HAHPS, 2020 1 0% NA not evaluable clinical improvementdetailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
Huang, 2020 1.37 [0.73; 2.56]
Hung et al., 2020 3.92 [1.66; 9.24]
1.49 [0.64 ; 3.48 ] GS-US-540-5773 (Goldman), 2020, Huang, 2020, Hung et al., 2020 3 86% 546 moderate not evaluable clinical improvement (14-day)detailed results GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
Huang, 2020 1.37 [0.73; 2.56]
1.48 [1.05 ; 2.08 ] GS-US-540-5773 (Goldman), 2020, Huang, 2020 2 0% 419 moderate not evaluable clinical improvement (7-day)detailed results GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
1.46 [0.95 ; 2.23 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable clinical improvement (time to event analysis only)detailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
Hung et al., 2020 3.92 [1.66; 9.24]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
1.15 [0.70 ; 1.87 ] GS-US-540-5773 (Goldman), 2020, Hung et al., 2020, Solaymani-Dodaran, 2021 3 84% 904 moderate not evaluable hospital dischargedetailed results HAHPS, 2020 0.91 [0.54; 1.54]
Huang, 2020 2.00 [1.15; 3.47]
1.34 [0.62 ; 2.90 ] HAHPS, 2020, Huang, 2020 2 76% 107 moderate not evaluable mechanical ventilationdetailed results Galan, 2021 0.14 [0.03; 0.71]
Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
0.53 [0.05 ; 5.86 ] Galan, 2021, Solaymani-Dodaran, 2021 2 87% 541 moderate not evaluable radiologic improvement (14-day)detailed results Huang, 2020 1.33 [0.94; 1.88]
1.33 [0.94 ; 1.88 ] Huang, 2020 1 0% 22 NA not evaluable radiologic improvement (7-day)detailed results Huang, 2020 2.40 [0.26; 22.51]
Ren, 2020 (REV) 0.05 [0.00; 1.17]
0.42 [0.01 ; 17.35 ] Huang, 2020, Ren, 2020 (REV) 2 74% 42 moderate not evaluable viral clearance detailed results Huang, 2020 1.20 [0.78; 1.85]
Hung et al., 2020 4.37 [1.86; 10.25]
Ren, 2020 (REV) 0.04 [0.00; 0.79]
1.19 [0.28 ; 5.11 ] Huang, 2020, Hung et al., 2020, Ren, 2020 (REV) 3 84% 169 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
4.37 [1.86 ; 10.25 ] Hung et al., 2020 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
Huang, 2020 1.09 [0.95; 1.26]
1.10 [0.95 ; 1.26 ] ELACOI (Lopinavir/ritonavir), 2020, Huang, 2020 2 0% 91 moderate not evaluable viral clearance by day 7detailed results ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
Huang, 2020 1.20 [0.60; 2.40]
Ren, 2020 (REV) 0.04 [0.00; 0.79]
0.82 [0.28 ; 2.35 ] ELACOI (Lopinavir/ritonavir), 2020, Huang, 2020, Ren, 2020 (REV) 3 58% 111 moderate not evaluable ICU admissiondetailed results Galan, 2021 1.42 [0.68; 2.99]
Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.30 [0.83 ; 2.04 ] Galan, 2021, Solaymani-Dodaran, 2021 2 0% 541 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
0.81 [0.64 ; 1.03 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 0.23 [0.01; 7.12]
Ren, 2020 (REV) 1.00 [0.02; 55.80]
0.43 [0.03 ; 5.81 ] Hung et al., 2020, Ren, 2020 (REV) 2 0% 147 moderate not evaluable adverse eventsdetailed results Huang, 2020 1.80 [0.14; 23.37]
Ren, 2020 (REV) 8.14 [0.35; 189.85]
3.29 [0.45 ; 23.99 ] Huang, 2020, Ren, 2020 (REV) 2 0% 42 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 06:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
